Novo Nordisk
Sells semaglutide and liraglutide and is developing CagriSema and amycretin for obesity and diabetes.
Share price
$38.64
Down 35% over 12 monthsWhat analysts expect
Hold
Buy20%
Hold60%
Sell20%
Price target for the next 12 months
$42.50Up 11% compared with the current price
Price now $38.42Average targetLowest $40.00 to highest $47.00
7 analysts. Targets from the past three months only. Source: TipRanks, 20 Oct 2026. Targets are opinions and are often wrong.
Business
- Yearly revenue
- $50B
- Yearly profit
- $18B
- Company value
- $169B
Revenue and profit for the last twelve months reported.
Peptides in this book
- SemaglutidePrescription
- LiraglutidePrescription
- CagriSemaUnder review
- AmycretinTrials only
Recent news
- 2026-10-01 Novo presents CagriSema weight management data at EASD 2026 GuruFocus
- 2026-10-02 Post hoc STEP UP analysis links Wegovy to lower liver fat RTTNews
- 2026-10-01 Regeneron drug added to semaglutide halves muscle loss in a trial Reuters
Risk in the news: A UBS analyst called the stock a possible value trap and expects a slow turnaround (The Motley Fool).
Prices are delayed and figures rounded. Not investment advice.